KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Travere Therapeutics (TVTX) over the last 13 years, with Q3 2025 value amounting to $1.3 million.

  • Travere Therapeutics' Other Working Capital Changes rose 16933.12% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year increase of 16775.32%. This contributed to the annual value of -$6.1 million for FY2024, which is 6123.96% up from last year.
  • Travere Therapeutics' Other Working Capital Changes amounted to $1.3 million in Q3 2025, which was up 16933.12% from $5.1 million recorded in Q2 2025.
  • Travere Therapeutics' Other Working Capital Changes' 5-year high stood at $38.9 million during Q3 2021, with a 5-year trough of -$6.4 million in Q2 2024.
  • In the last 5 years, Travere Therapeutics' Other Working Capital Changes had a median value of -$1.9 million in 2024 and averaged $609473.7.
  • As far as peak fluctuations go, Travere Therapeutics' Other Working Capital Changes crashed by 58288.04% in 2022, and later soared by 18021.05% in 2025.
  • Over the past 5 years, Travere Therapeutics' Other Working Capital Changes (Quarter) stood at -$1.9 million in 2021, then tumbled by 117.54% to -$4.0 million in 2022, then crashed by 38.4% to -$5.6 million in 2023, then soared by 89.98% to -$559000.0 in 2024, then skyrocketed by 337.39% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $5.1 million for Q2 2025, and $1.7 million during Q1 2025.